Aims: To develop an appropriate liposomal formulation for gene delivery against primary effusion lymphoma (PEL), a herpesvirus HHV8-associated B-cell lymphoma.
Materials & methods: Cationic, cationic PEGylated and cationic PEGylated anti-CD138 liposomes (ILp) linking a monoclonal antibody expressed on PEL cells were prepared by a thin layer evaporation method, followed by extrusion technique. The formulations were mixed with a model oligonucleotide to form the lipoplexes and tested on a BCBL-1 cell (a PEL cell line). The transfection efficiency was evaluated by flow cytometry and confocal laser scanning microscopy analysis.
Results: Based on antigen-antibody interaction, ILp mediated a specific gene delivery as shown by a significant increase in the transfection rate and a localized internalization of the oligonucleotide, in comparison with cationic liposomes and cationic PEGylated liposomes.
Conclusion: ILp could be proposed as effective carriers for oligonucleotide transfer in BCBL-1 cells. In vitro experimental results encourage us to further test the in vivo therapeutic potential of ILp for specific delivery of antitumoral agents.